Behavior Enhances Drug Reduction of Incontinence (BE-DRI)

NACompletedINTERVENTIONAL
Enrollment

307

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

August 31, 2006

Conditions
Urinary Incontinence (UI)
Interventions
DRUG

Tolterodine

4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.

BEHAVIORAL

Behavioral training

Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.

Trial Locations (9)

15213

University of Pittsburgh, Pittsburgh

21201

University of Maryland, Baltimore

35233

University of Alabama, Birmingham

48123

Oakwood Hospital and Medical Center, Royal Oak

60153

Loyola University Medical Center, Maywood

75390

University of Texas Southwestern, Dallas

78229

University of Texas Health Sciences Center, San Antonio

84132

University of Utah, Salt Lake City

92103

University of California, San Diego

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Carelon Research

OTHER